Recombinant two-component COVID-19 vaccine (CHO cell)

BIOLOGICAL3 trials

Sponsors

Jiangsu Rec-Biotechnology Co., Ltd.

Conditions

COVID-19Covid19

Early Phase 1

Safety, Reactogenicity and Immunogenicity Study of ReCOV

CompletedNCT04818801

Jiangsu Rec-Biotechnology Co., Ltd.Covid19

Start: 2021-06-18End: 2022-05-05Updated: 2022-09-27

Phase 2

Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)

CompletedNCT05323435

Jiangsu Rec-Biotechnology Co., Ltd.COVID-19

Start: 2022-05-30End: 2023-01-16Updated: 2023-04-25

Phase 3

Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov)

CompletedNCT05398848

Jiangsu Rec-Biotechnology Co., Ltd.COVID-19

Start: 2022-10-31End: 2023-12-29Updated: 2024-02-29

Related Papers

Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies

Expert Review of Vaccines2024-03-26

Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies

Infectious Diseases and Therapy2023-12-161 citations